Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...

A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...

Each immune cell group has distinct metabolic requirements, activation pathways, and cytokine reliance. Standard, one-size-fits-all media cannot address these features. When studying diverse cell ...

A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...

Novartis received breakthrough therapy designation from the FDA for ianalumab, a monoclonal antibody aimed at treating Sjögren’s disease. Ianalumab works by depleting B cells and blocking BAFF-R ...

Novartis intends to submit ianalumab for regulatory approval globally in early 2026.

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...

Recent findings suggest that the Epstein-Barr virus (EBV) is involved in both causing multiple sclerosis (MS) and shaping its ...